Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
www.DrugChatter.com/monitoring/
Does probenecid increase tigecycline's serum concentration?Are there any risks in combining lipitor and peppermint oil?Can acyclovir be taken for longer than a week?How many lipitor users experience flexibility improvement?Are dosage adjustments needed with iron rich diets?
See the DrugPatentWatch profile for keytruda
When Was Keytruda First Approved by the FDA? In 2014, [1] the US Food and Drug Administration (FDA) approved Keytruda (pembrolizumab), a checkpoint inhibitor, for the treatment of patients with advanced melanoma, a type of skin cancer. This marked the first FDA approval for a cancer drug targeting the PD-1 receptor pathway. What Was the Significance of This Approval? At the time of its approval, Keytruda was seen as a breakthrough treatment for patients with advanced melanoma, particularly those who had failed prior treatments [2]. The approval was a significant milestone in the development of immunotherapy for cancer treatment, which works by harnessing the body's immune system to fight cancer. Keytruda's Subsequent Approval for Other Cancer Types Since its initial approval for melanoma, Keytruda has received additional FDA approvals for various other types of cancer, including [3] : - Head and neck cancer (2016) - Non-small cell lung cancer (NSCLC) (2017) - Small cell lung cancer (2019) - Triple-negative breast cancer (2019) - Renal cell carcinoma (2020) - Cervical cancer (2021) Clinical Data and Patient Outcomes According to clinical trials, Keytruda has demonstrated significant improvements in overall survival and tumor response rates across various cancer types [4]. However, patients should consult their healthcare provider about potential side effects and the risks associated with treatment. Regulatory Approval and Patent Watch As Keytruda's patents expire in various jurisdictions, biosimilar manufacturers are expected to enter the market, potentially increasing competition and driving down prices [5]. The timeline for patent expiration varies by country, but in the US, the exclusivity period for Keytruda's patent is set to expire in 2028. Sources: [1] https://www.fda.gov/news-events/press-announcements/fda-approves-keytruda-treat-certain-patients-advanced-melanoma [2] https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/pembrolizumab.html [3] https://www.merckmg.com/our-products/merck-portfolio/keytruda/ [4] https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab [5] https://www.drugpatentwatch.com/drugs/keytruda-pembrolizumab
Other Questions About Keytruda :